GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Athira Pharma Inc (NAS:ATHA) » Definitions » Accounts Receivable

ATHA (Athira Pharma) Accounts Receivable : $0.00 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Athira Pharma Accounts Receivable?

Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Athira Pharma's accounts receivables for the quarter that ended in Dec. 2024 was $0.00 Mil.

Accounts receivable can be measured by Days Sales Outstanding.

In Ben Graham's calculation of Net-Net Working Capital, accounts receivable are only considered to be worth 75% of book value. Athira Pharma's Net-Net Working Capital per share for the quarter that ended in Dec. 2024 was $0.97.


Athira Pharma Accounts Receivable Historical Data

The historical data trend for Athira Pharma's Accounts Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Athira Pharma Accounts Receivable Chart

Athira Pharma Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Accounts Receivable
Get a 7-Day Free Trial - - - - -

Athira Pharma Quarterly Data
Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24
Accounts Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Athira Pharma Accounts Receivable Calculation

Accounts Receivable is money owed to a business by customers and shown on its Balance Sheet as an asset.


Athira Pharma Accounts Receivable Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's accounts receivables are being managed.

Athira Pharma's Days Sales Outstanding for the quarter that ended in Dec. 2024 is calculated as:

2. In Ben Graham's calculation of Net-Net Working Capital (NNWC), Athira Pharma's accounts receivable are only considered to be worth 75% of book value:

Athira Pharma's Net-Net Working Capital Per Share for the quarter that ended in Dec. 2024 is calculated as:

Net-Net Working Capital Per Share
=(Cash And Cash Equivalents+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(51.275+0.75 * 0+0.5 * 0-13.938
-0-0)/38.669
=0.97

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net receivables tells us a great deal about the different competitors in the same industry. In competitive industries, some attempt to gain advantage by offering better credit terms, causing increase in sales and receivables.

If company consistently shows lower % Net receivables to gross sales than competitors, then it usually has some kind of competitive advantage which requires further digging.

Average Days Sales Outstanding is a good indicator for measuring a company's sales channel and customers. A company may book great revenue and earnings growth but never receive payment from their customers. This may force a write-off in the future and depress future earnings.


Athira Pharma Accounts Receivable Related Terms

Thank you for viewing the detailed overview of Athira Pharma's Accounts Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Athira Pharma Business Description

Traded in Other Exchanges
N/A
Address
18706 North Creek Parkway, Suite 104, Bothell, WA, USA, 98011
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) a subcutaneously administered, small molecule positive modulator of the HGF/MET system for CNS disorders, ATH-1020 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system. ATH-1105 is a novel small molecule compound designed to be an orally available once-daily treatment, to enhance the HGF/MET system, and several other compounds in preclinical discovery and development for neurodegenerative diseases, including ATH-1018 and ATH-1019.
Executives
Mark James Litton officer: Chief Operating Officer 11804 NORTH CREEK PARKWAY SOUTH, BOTHELL WA 98011
Mark Worthington officer: General Counsel C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Kevin Church officer: Vice President of Discovery 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Rachel Lenington officer: Chief Technology Officer C/O ATHIRA PHARMA, INC., 18706 NORTH CREEK PARKWAY, SUITE 104, BOTHELL WA 98011
Andrew Gengos officer: See Below 21900 BURBANK BOULEVARD, 3RD FLOOR, WOODLAND HILLS CA 91367
Kelly A Romano director C/O DORMAN PRODUCTS, INC., 3400 EAST WALNUT STREET, COLMAR PA 18915
Perceptive Life Sciences Master Fund Ltd 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Grant Pickering director C/O VAXCYTE, INC., 825 INDUSTRIAL ROAD, STE. 300, SAN CARLOS CA 94070
James A Johnson director C/O ZYMOGENETICS, INC., 1201 EASTLAKE AVENUE, SEATTLE WA 98102
Glenna Mileson officer: Chief Financial Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Hans Moebius officer: Chief Medical Officer 4000 MASON ROAD, SUITE 300, BOX 352141, SEATTLE WA 98195-2141
Michael A. Panzara director 733 CONCORD AVENUE, CAMBRIDGE MA 02138
Barbara Kosacz director 3175 HANOVER STREET, PALO ALTO CA 94304
Joseph Edelman director, 10 percent owner C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Rtw Investments, Lp 10 percent owner 40 10TH AVENUE, 7TH FLOOR, NEW YORK NY 10014